Credit Suisse Ag C4 Therapeutics, Inc. Transaction History

Credit Suisse Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$3.1 - $9.02 $24 - $72	8 Added 0.03%	25,997 $81,000
Q4 2022 Feb 13, 2023	BUY	$5.42 - $10.24 $10,617 - $20,060	1,959 Added 8.15%	25,989 $153,000
Q3 2022 Nov 10, 2022	BUY	$8.03 - $12.77 $99,298 - $157,913	12,366 Added 106.02%	24,030 $211,000
Q2 2022 Aug 12, 2022	BUY	$5.06 - $26.46 $8,804 - $46,040	1,740 Added 17.53%	11,664 $88,000
Q1 2022 May 16, 2022	BUY	$19.99 - $33.23 $12,713 - $21,134	636 Added 6.85%	9,924 $240,000
Q4 2021 Feb 14, 2022	BUY	$29.39 - $46.86 $22,277 - $35,519	758 Added 8.89%	9,288 $298,000
Q3 2021 Nov 12, 2021	SELL	$35.91 - $50.5 $2,082 - $2,929	-58 Reduced 0.68%	8,530 $380,000
Q2 2021 Aug 16, 2021	BUY	$30.39 - $42.18 $260,989 - $362,241	8,588 New	8,588 $324,000

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $214M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.